Literature DB >> 1836316

Sensitivity to curare in patients with upper and lower motor neurone dysfunction.

F Fiacchino1, M Gemma, M Bricchi, S Giombini, B Regi.   

Abstract

Sensitivity to the action of nondepolarising relaxants was compared in muscles of upper and lower limbs in four syringomyelic patients undergoing elective neurosurgical procedures. It was observed that muscles with signs of lower motor neurone dysfunction are supersensitive to the action of nondepolarising relaxants. Terminal sprouting of motor axons and the occurrence of newly formed neuromuscular junctions may be responsible for a low synaptic efficacy and may explain the high sensitivity to factors that reduce the safety margin of neuromuscular transmission.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1836316     DOI: 10.1111/j.1365-2044.1991.tb09864.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  5 in total

Review 1.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 2.  [Neuromuscular monitoring in patients with neuromuscular diseases. Options and needs].

Authors:  A Beloiartsev; S Gableske; M Hübler
Journal:  Anaesthesist       Date:  2009-07       Impact factor: 1.041

Review 3.  Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review.

Authors:  Chafic Y Karam; Sabrina Paganoni; Nanette Joyce; Gregory T Carter; Richard Bedlack
Journal:  Am J Hosp Palliat Care       Date:  2014-09-08       Impact factor: 2.500

4.  Anesthetic management during Cesarean section in a woman with residual Arnold-Chiari malformation Type I, cervical kyphosis, and syringomyelia.

Authors:  Ramsis F Ghaly; Kenneth D Candido; Ruben Sauer; Nebojsa Nick Knezevic
Journal:  Surg Neurol Int       Date:  2012-02-15

5.  Is succinylcholine appropriate or obsolete in the intensive care unit?

Authors:  L H Booij
Journal:  Crit Care       Date:  2001-08-31       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.